A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment.
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 13 Sep 2017 Status changed from recruiting to completed.
- 08 May 2010 New trial record